Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
FundaMental Pharma is a neuroscience company with a portfolio at the preclinical stage.
Hyku is a biotech company that develops precise covalent targeting of disease-causing proteins.
Tagworks Pharmaceuticals is a privately held biotech company
Amphista Therapeutics operates as a biopharmaceutical company.
Anokion is harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance.
Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.
Kedalion Therapeutics is a biotechnology company that develops and commercializes transformative topical ophthalmic therapies.
Soteria is a biotechnology company that develops immunotherapies to treat cancer patients
Arctos Medical is a developed gene therapy that does not correct rare genetic eye diseases but much more common cases of blindness.
Forendo Pharma is a developer of novel drugs intended for the treatment of urological and other endocrinological diseases.
Aelin Therapeutics is a provider of a biotherapeutics platform technology called pept-ins that are intended to harnesses.
NeuroVia is a biopharmaceutical company.
Thesan Pharmaceuticals is a preclinical biopharmaceutical company developing novel therapeutics for skin disorders.
Novartis Venture Fund has invested in 37 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Novartis Venture Fund's top investment sectors include Biotechnology, Health Care, Therapeutics, Biopharma, Medical. The firm invests across 9 different industry categories.
Among tracked funding rounds, Anaveon received $119.7M in a Series B round. Novartis Venture Fund's total known invested capital is $1.8B.
Novartis Venture Fund's average investment size is $50.8M across its portfolio of 37 companies.
Recent Novartis Venture Fund portfolio additions include FundaMental Pharma, Hyku, Tagworks Pharmaceuticals, Amphista Therapeutics, Anokion. These companies were founded in 2020 or later.